Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores by Vilhjalmsson, B. J. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2015
Modeling Linkage Disequilibrium Increases
Accuracy of Polygenic Risk Scores
B. J. Vilhjalmsson
J. Yang
H. K. Finucane
A. Gusev
S. Lindstrom
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Psychiatry Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.
Recommended Citation
Vilhjalmsson B, Yang J, Finucane H, Gusev A, Lindstrom S, Ripke S, Tamimi R, Stahl E, Price A, Lencz T, . Modeling Linkage
Disequilibrium Increases Accuracy of Polygenic Risk Scores. . 2015 Jan 01; 97(4):Article 934 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/934. Free full text article.
Authors
B. J. Vilhjalmsson, J. Yang, H. K. Finucane, A. Gusev, S. Lindstrom, S. Ripke, R. Tamimi, E. Stahl, A. L. Price,
T. Lencz, and +25 additional authors
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/934
ARTICLE
Modeling Linkage Disequilibrium
Increases Accuracy of Polygenic Risk Scores
Bjarni J. Vilhja´lmsson,1,2,3,4,* Jian Yang,5,6 Hilary K. Finucane,1,2,3,7 Alexander Gusev,1,2,3
Sara Lindstro¨m,1,2 Stephan Ripke,8,9,10 Giulio Genovese,3,8,11 Po-Ru Loh,1,2,3 Gaurav Bhatia,1,2,3
Ron Do,12,13 Tristan Hayeck,1,2,3 Hong-Hee Won,3,14 Schizophrenia Working Group of the Psychiatric
Genomics Consortium, Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE)
study, Sekar Kathiresan,3,14 Michele Pato,15 Carlos Pato,15 Rulla Tamimi,1,2,16 Eli Stahl,3,13,17,18
Noah Zaitlen,19 Bogdan Pasaniuc,20 Gillian Belbin,12,13 Eimear E. Kenny,12,13,18,21 Mikkel H. Schierup,4
Philip De Jager,3,22,23 Nikolaos A. Patsopoulos,3,22,23 Steve McCarroll,3,8,11 Mark Daly,3,8
Shaun Purcell,3,13,17,18 Daniel Chasman,22,24 Benjamin Neale,3,8 Michael Goddard,25,26
Peter M. Visscher,5,6 Peter Kraft,1,2,3,27 Nick Patterson,3 and Alkes L. Price1,2,3,27,*
Polygenic risk scores have shown great promise in predicting complex disease risk andwill becomemore accurate as training sample sizes
increase. The standard approach for calculating risk scores involves linkage disequilibrium (LD)-based marker pruning and applying a
p value threshold to association statistics, but this discards information and can reduce predictive accuracy. We introduce LDpred, a
method that infers the posterior mean effect size of each marker by using a prior on effect sizes and LD information from an external
reference panel. Theory and simulations show that LDpred outperforms the approach of pruning followed by thresholding, particularly
at large sample sizes. Accordingly, predicted R2 increased from 20.1% to 25.3% in a large schizophrenia dataset and from 9.8% to 12.0%
in a large multiple sclerosis dataset. A similar relative improvement in accuracy was observed for three additional large disease datasets
and for non-European schizophrenia samples. The advantage of LDpred over existing methods will grow as sample sizes increase.
Introduction
Polygenic risk scores (PRSs) computed from genome-wide
association study (GWAS) summary statistics have proven
valuable for predicting disease risk and understanding the
genetic architecture of complex traits. PRSs were used for
predicting genetic risk in a schizophrenia (SCZ) GWAS
for which there was only one genome-wide-significant lo-
cus1 and have been widely used for predicting genetic risk
for many traits.1–14 PRSs can also be used for drawing infer-
ences about genetic architectures within and across
traits.11,12,15–17 As GWAS sample sizes grow, the prediction
accuracy of PRSs will increase and might eventually yield
clinically actionable predictions.15,18–20 However, as noted
in recent work,18 current PRS methods do not account for
the effects of linkage disequilibrium (LD), which limits
their predictive value, especially for large samples.
Indeed, our simulations show that, in the presence of
LD, the prediction accuracy of the widely used approach
of LD pruning followed by p value thresholding
(PþT)1,6,8,9,11,12,14,15,18,19 falls short of the heritability ex-
plained by the SNPs (Figure 1 and Figure S1; see Material
and Methods).
One possible solution to this problem is to use one of the
many available prediction methods that require genotype
data as input. These include genomic BLUP—which as-
sumes an infinitesimal distribution of effect sizes—and
its extensions to non-infinitesimal mixture priors.21–28
However, these methods are not applicable to GWAS sum-
mary statistics when genotype data are unavailable
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because of privacy concerns or logistical constraints, as is
often the case. In addition, many of thesemethods become
computationally intractable at the very large sample sizes
(>100,000 individuals) that would be required for
achieving clinically relevant predictions for most common
diseases.15,18,19
In this study, we propose LDpred, a Bayesian PRS that
estimates posterior mean causal effect sizes from GWAS
summary statistics by assuming a prior for the genetic ar-
chitecture and LD information from a reference panel. By
using a point-normal mixture prior25,29 for the marker
effects, LDpred can be applied to traits and diseases with
a wide range of genetic architectures. Unlike PþT, LDpred
has the desirable property that its prediction accuracy
converges to the heritability explained by the SNPs as
sample size grows (see below). Using simulations based
on real genotypes, we compare the prediction accuracy
of LDpred to that of the widely used approach of
PþT,1,6,8,9,11,12,14,15,18,19,30 as well as other approaches
that train on GWAS summary statistics. We apply LDpred
to seven common diseases for which raw genotypes are
available in small sample size and to five common diseases
for which only summary statistics are available in large
sample size.
Material and Methods
Overview of Methods
LDpred calculates the posterior mean effects fromGWAS summary
statistics by conditioning on a genetic architecture prior and LD
information from a reference panel. The inner product of these
re-weighted and the test-sample genotypes is the posterior mean
phenotype and thus, under the model assumptions and available
data, an optimal (minimum variance and unbiased) predictor.31
The prior for the effect sizes is a point-normal mixture distribu-
tion, which allows for non-infinitesimal genetic architectures.
The prior has two parameters: the heritability explained by the ge-
notypes and the fraction of causal markers (i.e., the fraction of
markers with non-zero effects). The heritability parameter is esti-
mated from GWAS summary statistics and accounts for sampling
noise and LD32–34 (see details below). The fraction of causal
markers is allowed to vary and can be optimized with respect to
prediction accuracy in a validation dataset, analogous to how
PþT is applied in practice. Hence, similar to PþT (where p value
thresholds are varied and multiple PRSs are calculated), multiple
LDpred risk scores are calculated with the use of priors with vary-
ing fractions of markers with non-zero effects. The value that
optimizes prediction accuracy can then be determined in an inde-
pendent validation dataset. We approximate LD by using data
from a reference panel (e.g., independent validation data). We es-
timate the posterior mean effect sizes via the Markov chainMonte
Carlo (MCMC) method and apply them to validation data to
obtain PRSs. In the special case of no LD, posterior mean effect
sizes with a point-normal prior can be viewed as a soft threshold
and can be computed analytically (Figure S2; see details below).
We have released open-source software implementing the method
(see Web Resources).
A key feature of LDpred is that it relies on GWAS summary sta-
tistics, which are often available evenwhen raw genotypes are not.
In our comparison of methods, we therefore focus primarily on
PRSs that rely on GWAS summary statistics. The main approaches
that we compare with LDpred are listed in Table S1. These include
PRS based on all markers (unadjusted PRS), PþT, and LDpred
specialized to an infinitesimal prior (LDpred-inf) (see details
below). We note that LDpred-inf is an analytic method, given
that posterior mean effects are closely approximated by
E

b j ~b;Dz M
Nh2g
I þD
!1
~b; (Equation 1)
where D denotes the LD matrix between the markers in the
training data, and ~b denotes the marginally estimated marker ef-
fects (see details below). LDpred-inf (using GWAS summary statis-
tics) is analogous to genomic BLUP (using raw genotypes) because
it assumes the same prior.
Phenotype Model
Let Y be a N31 phenotype vector and X be a N3M genotype ma-
trix, whereN is the number of individuals, andM is the number of
genetic variants. For simplicity, we will assume throughout that
the phenotype Y and individual genetic variants Xi have been
A B Figure 1. Prediction Accuracy of PþT
Applied to Simulated Genotypes with
and without LD
The performance of PþT, PRSs based on
LD-pruned SNPs (r2 < 0.2) followed by p
value thresholding with an optimized
threshold, when applied to simulated
genotypes with and without LD. The pre-
diction accuracy, as measured by squared
correlation between the true phenotypes
and the PRSs (prediction R2), is plotted as
a function of the training sample size.
The results are averaged over 1,000 simu-
lated traits with 200,000 simulated geno-
types, where the fraction of causal variants
pwas allowed to vary. In (A), the simulated
genotypes are unlinked. In (B), the simu-
lated genotypes are linked; we simulated
independent batches of 100 markers while
fixing the squared correlation between
adjacent variants in a batch at 0.9.
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mean centered and standardized to have variance 1. Wemodel the
phenotype as a linear combination ofM genetic effects and an in-
dependent environmental effect ε, i.e., Y ¼PMi¼1Xibi þ ε, whereXi
denotes the ith genetic variant, bi is its true effect, and ε is the envi-
ronmental and noise contribution. In this setting, the (marginal)
least-squares estimate of an individual marker effect isbbi ¼ X0iY=N. For clarity, we implicitly assume that we have the
standardized effect estimates available to us as summary statistics.
In practice, we usually have other summary statistics, including
the p value and direction of the effect estimates, from which we
infer the standardized effect estimates. First, we exclude all
markers with ambiguous effect directions, i.e., A/T and G/C
SNPs. Second, from the p values we obtain Z scores and multiply
them by the sign of the effects (obtained from the effect estimates
or effect direction). Finally, we approximate the least-squares esti-
mate for the effect by bbi ¼ siðzi= ﬃﬃﬃﬃNp Þ, where si is the sign, and zi is
the Z score obtained from the p value. If the trait is a case-control
trait, this transformation from the p value to the effect size can be
thought of as being an effect estimate for an underlying quantita-
tive liability or risk trait.35
Unadjusted PRS
The unadjusted PRS is simply the sum of all the estimated marker
effects for each allele, i.e., the standard unadjusted polygenic score
for the ith individual is Si ¼
PM
j¼1Xjibbj, where Xji denotes the geno-
type for the ith individual and the jth genetic variant.
PþT
In practice, the prediction accuracy is improved if the markers are
LD pruned and p value pruned a priori. Informed LD pruning
(also known as LD clumping), which preferentially prunes the
less significant marker, often yields much more accurate predic-
tions than pruning randommarkers. Applying a p value threshold,
i.e., using onlymarkers that achieve a given significance threshold,
also improves prediction accuracies formany traits and diseases. In
this paper, PþT refers to the strategy of first applying informed LD
pruning with r2 threshold 0.2 and subsequently applying p value
thresholding, where the p value threshold is optimized over a
grid with respect to prediction accuracy in the validation data.
Bpred: Bayesian Approach in the Special Case
of No LD
Under a model, the optimal linear prediction given some statistic
is the posterior mean prediction. This prediction is optimal in the
sense that it minimizes the prediction error variance.36 Under the
linear model described above, the posterior mean phenotype
given GWAS summary statistics and LD is
E

Y j ~b; bD ¼XM
i¼1
X0iE

bi j ~b; bD:
Here, ~b denotes a vector of marginally estimated least-squares es-
timates obtained from the GWAS summary statistics, and bD refers
to the observed genome-wide LD matrix in the training data, i.e.,
the samples for which the effect estimates are calculated. Hence,
the quantity of interest is the posterior mean marker effect given
LD information from the GWAS sample and the GWAS summary
statistics. In practice, we might not have this information avail-
able to us and are forced to estimate the LD from a reference panel.
In most of our analyses, we estimated the local LD structure in the
training data from the independent validation data. Although this
choice of LD reference panel can lead to small bias when one esti-
mates individual prediction accuracy, this choice is valid when-
ever the aim is to calculate accurate PRSs for a cohort without
knowing the case-control status a priori. In other words, it is an
unbiased estimate for the PRS accuracy when the validation data
are used as an LD reference, which we recommend in practice.
The variance of the trait can be partitioned into a heritable part
and the noise, i.e., VarðYÞ ¼ h2gQþ ð1 h2g ÞI, where h2g denotes the
heritability explained by the genotyped variants, and Q ¼ XX0=M
is the SNP-based genetic relationship matrix. We can obtain a trait
with the desired covariance structure if we sample the betas
independently with mean 0 and variance h2g=M. Note that if the ef-
fects are independently sampled, then this also holds true for corre-
latedgenotypes, i.e.,when there isLD.However, LDwill increase the
variance of heritability explained by the genotypes as estimated
from the data (as a result of fewer effective independent markers).
If all samples are independent and all markers are unlinked and
have effects drawn from a Gaussian distribution, i.e.,
biiidNð0; ðh2g=MÞÞ, then this is an infinitesimal model,37 where
all markers are causal. Under this model, the posterior mean can
be derived analytically, as shown by Dudbridge15:
E

bi j ~b
 ¼ Ebi j ~bi ¼
 
h2g
h2g þ MN
!
~bi:
Interestingly, with unlinked markers, the infinitesimal shrink
factor times the heritability, i.e., 
h2g
h2g þ MN
!
h2g ;
is the expected squared correlation between the unadjusted PRS
(with unlinked markers) and the phenotype, regardless of the
underlying genetic architecture.38,39
An arguably more reasonable prior for the effect sizes is a non-
infinitesimal model, where only a fraction of the markers are
causal. For this, consider the following Gaussian mixture prior:
biiid
8><>:
N
 
0;
h2g
Mp
!
with probability p
0 with probability ð1 pÞ;
where p is the probability that a marker is drawn from a Gaussian
distribution, i.e., the fraction of causal markers. Under this model,
the posterior mean can be derived as (see Appendix A)
E

bi j ~bi
 ¼
 
h2g
h2g þ
Mp
N
!
pi
~bi;
where pi is the posterior probability that the i
thmarker is causal and
can be calculated analytically (see Equation A1 in Appendix A).
In our simulations, we refer to this Bayesian shrink without LD as
Bpred.
LDpred: Bayesian Approach in the Presence of LD
If we allow for loci to be linked, then we can derive posterior mean
effects analytically under a Gaussian infinitesimal prior (described
above). We call the resulting method LDpred-inf, and it represents
a computationally efficient special case of LDpred. If we assume
that distantmarkers are unlinked, the posteriormean for the effect
sizes within a small region l under an infinitesimal model is well
approximated by
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E

bl j ~bl;Dz M
Nh2g
I þDl
!1
~b
l
:
Here,Dl denotes the regional LDmatrix within the region of LD,
and ~b
l
denotes the least-squares-estimated effects within that re-
gion. The approximation assumes that the heritability explained
by the region is small and that LD with SNPs outside of the region
is negligible. Interestingly, under these assumptions the resulting
effects approximate the standard mixed-model genomic BLUP ef-
fects. LDpred-inf is therefore a natural extension of the genomic
BLUP to summary statistics. A more detailed derivation is given
in Appendix A. In practice, we do not know the LD pattern in
the training data, and we need to estimate it by using LD in a refer-
ence panel.
Deriving an analytical expression for the posteriormean under a
non-infinitesimal Gaussian mixture prior is difficult, and thus
LDpred approximates it numerically by using an approximate
MCMC Gibbs sampler. This is similar to the Gauss-Seidel
approach, except that instead of using the posterior mean to up-
date the effect size, we sample the update from the posterior distri-
bution. Compared to the Gauss-Seidel method, this seems to lead
to less serious convergence issues. The approximate Gibbs sampler
is described in detail in Appendix A. To ensure convergence, we
shrink the posterior probability of being causal by a fixed factor
at each big iteration step i, where the shrinkage factor is defined
as c ¼ minð1; ðbh2g=ð~h2g ÞiÞÞ, where bh2g is the estimated heritability
based on an aggregate approach (see below), and ð~h2g Þi is the esti-
mated genome-wide heritability at each big iteration. To speed
up convergence in the Gibbs sampler, we used Rao-Blackwelliza-
tion and observed that good convergence was usually attained
with fewer than 100 iterations in practice (see Appendix A).
Estimation of the Heritability Parameter
In the absence of population structure and assuming independent
and identically distributed mean-zero SNP effects, the following
equation has been shown to hold:
E

c2j
 ¼ 1þNh2g lj
M
;
where c2j is the c
2-distributed test statistic at the jth SNP, and
lj ¼
P
k½r2ðj; kÞ  ð1 r2ðj; kÞ=N  2Þ, summing over k neighboring
SNPs in LD, is the LD score for the jth SNP. Taking the average of
both sides over SNPs and rearranging, we obtain a heritability
estimate:
~h
2
g ¼

c2  1M
lN
;
where c2 ¼Pjðc2j =MÞ and l ¼Pjðlj=MÞ. We call this the aggregate
estimator, and it is equivalent to LD-score regression32–34 with
intercept constrained to 1 and SNP j weighted by 1=lj. Prediction
accuracy is not predicated on the robustness of this estimator,
which will be evaluated elsewhere. Following the conversion pro-
posed by Lee et al.,40 we also report the heritability on the liability
scale.
Practical Considerations
When LDpred is applied to real data, two parameters need to be
specified beforehand. The first parameter is the LD radius, i.e.,
the number of SNPs that we adjust for on each side of a given
SNP. There is a trade-off when we decide on the LD radius. If the
LD radius is too large, then errors in LD estimates can lead to
apparent LD between unlinked loci, which can lead to worse effect
estimates and poor convergence. If the LD radius is too small, then
we risk not accounting for LD between linked loci.We found that a
LD radius of approximatelyM/3,000 (the default value in LDpred),
where M is the total number of SNPs used in the analysis, works
well in practice; this corresponds to a 2 Mb LD window on average
in the genome. We also note that LDpred is implemented with a
sliding window along the genome, whereas LDpred-inf is imple-
mented with tiling LD windows, because this is computationally
more efficient and does not affect accuracy. Regarding choice of
the LD panel, its LD structure should ideally be similar to the
training data for which the summary statistics are calculated. In
simulations, we found that the LD reference panel should contain
at least 1,000 individuals.
The second parameter is the fraction p of non-zero effects in the
prior. This parameter is analogous to the p value threshold used in
PþT. Our recommendation is to try a range of values for p (e.g., 1,
0.3, 0.1, 0.03, 0.01, 0.003, 0.001, 3E4, 1E4, 3E5, 1E5; these
are default values in LDpred). This will generate 11 sets of SNP
weights, which can be used for calculating polygenic scores. One
can then use independent validation data to optimize the param-
eter, analogous to how the p value threshold is optimized in the
PþT method.
Whenusing LDpred,we recommend that SNPweights (posterior
mean effect sizes) are calculated for exactly the SNPs used in the
validation data. This ensures that all SNPs with non-zero weights
are in the validation dataset. In practice, we use the intersection
of SNPs present in the summary-statistics dataset, the LD reference
genotypes, and the validation genotypes. If the validation cohort
contains more than 1,000 individuals, with the same ancestry as
the individuals used for theGWAS summary statistics, thenwe sug-
gest using the validation cohort as the LD reference as well. These
steps are implemented in the LDpred software package.
Simulations
We performed three types of simulations: (1) simulated traits and
simulated genotypes; (2) simulated traits, simulated summary sta-
tistics, and simulated validation genotypes; and (3) simulated
traits based on real genotypes. For most of the simulations, we
used the point-normal model for effect sizes as described above:
biiid
8><>:
N
 
0;
h2g
Mp
!
with probability p
0 with probability ð1 pÞ:
For some of our simulations (Figure S5), we sampled the non-
zero effects from a Laplace distribution instead of a Gaussian dis-
tribution. For all of our simulations, we used four different values
for p (the fraction of causal loci). For some of our simulations
(Figure S1), we sampled the fraction of causal markers within a re-
gion from a Beta(p, 1  p) distribution. This simulates a genetic ar-
chitecture where causal variants cluster in certain regions of the
genome. We then obtained the simulated trait by summing up
the allelic effects for each individual and adding a Gaussian-
distributed noise term to fix the heritability. The simulated geno-
types were sampled from a standard Gaussian distribution. To
emulate LD, we simulated one genotype or SNP at a time to
generate batches of 100 correlated SNPs. Each SNP was defined
as the sum of the preceding adjacent SNP and some noise, where
they were scaled to correspond to a fixed squared correlation be-
tween two adjacent SNPs within a batch. We simulated genotypes
with the adjacent squared correlation between SNPs set to 0 (un-
linked SNPs) and 0.9 (SNPs in LD).
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In order to compare the performance of ourmethod at large sam-
ple sizes, we simulated summary statistics that we used as training
data for the PRSs.We also simulated two smaller samples (2,000 in-
dividuals) representing independentvalidationdata and a LD refer-
ence panel. When there is no LD, the least-squares effect estimates
(summary statistics) are sampled from a Gaussian distribution,bbi  biiidNðbi; ð1=NÞÞ, where bi are the true effects. To simulatemar-
ginal effect estimates without genotypes in the presence of LD, we
first estimate the LD pattern empirically by simulating 100 linked
SNPs for 1,000 individuals for a given value (as described above)
and average over 1,000 simulations. This matrix captures the LD
pattern in the validation data given that we simulate it by using
the same procedure. Using this LD matrix D, we then sample the
marginal least-squares estimateswithin a regionof LD (SNP chunk)
as bb  biidNðDb; ðD=NÞÞ, where D is the LD matrix.
For the simulations in Figure 1B and Figures S1, S3, and S4, we
simulated least-squares effect estimates for 200,000 variants in
batches of LD regions with 100 variants each (as described above).
We then simulated genotypes for 2,000 validation individuals and
averaged over 100–3,000 simulated phenotypes to ensure smooth
curves. Depending on the simulation parameters, the actual num-
ber of repeats required for achieving a smooth curve varied. For the
simulations in Figure 1A and Figure S2, we simulated the least-
squares estimates independently by adding an appropriately
scaled Gaussian noise term to the true effects.
When simulating traits by using the Wellcome Trust Case Con-
trol Consortium (WTCCC) genotypes (Figure 2), we performed
simulations under four different scenarios representing different
number of chromosomes: (1) all chromosomes, (2) chromosomes
1–4, (3) chromosomes 1 and 2, and (4) chromosome 1. We used
16,179 individuals in the WTCCC data and 376,901 SNPs that
passed quality control (QC). In our simulations, we used 3-fold
cross-validation, whereby 1/3 of the data were validation data
and 2/3 were training data.
WTCCC Genotype Data
We used the WTCCC genotypes41 for both simulations and anal-
ysis. After performing QC, pruning variants with missing rates
above 1%, and removing individuals with genetic relatedness co-
efficients above 0.05, we were left with 15,835 individuals geno-
typed for 376,901 SNPs, including 1,819 individuals with bipolar
disease (BD), 1,862 individuals with coronary artery disease
(CAD), 1,687 individuals with Crohn disease (CD), 1,907 individ-
uals with hypertension (HT), 1,831 individuals with rheumatoid
arthritis (RA), 1,953 individuals with type 1 diabetes (T1D), and
1,909 individuals with type 2 diabetes (T2D). For each of the seven
diseases, we performed 5-fold cross-validation on affected individ-
uals and 2,867 control individuals. For each of these analyses, we
used the validation data as the LD reference data when using
LDpred and when performing LD pruning.
Summary Statistics and Independent Validation
Datasets
Six large summary-statistics datasets were analyzed in this study.
The Psychiatric Genomics Consortium 2 (PGC2) SCZ summary
statistics14 consisted of 34,241 affected and 45,604 control indi-
viduals. For our purposes, we calculated GWAS summary statistics
while excluding the ISC (International Schizophrenia Con-
sortium) cohorts and the MGS (Molecular Genetics of Schizo-
phrenia) cohorts. All subjects in these cohorts provided informed
consent for this research, and procedures followed were in accor-
dance with ethical standards. The summary statistics were calcu-
lated on a set of 1000 Genomes imputed SNPs, resulting in
16.9 million statistics. The two independent validation datasets,
the ISC and MGS datasets, both consist of multiple cohorts with
individuals of European descent. For both of the validation data-
sets, we used the chip genotypes and filtered individuals with
more than 10% of genotype calls missing and filtered SNPs that
had a missing rate more than 1% and a minor allele frequency
(MAF) greater than 1%. In addition, we removed SNPs that had
ambiguous nucleotides, i.e., A/T and G/C. We matched the SNPs
between the validation and GWAS summary-statistics datasets
on the basis of the SNP rsID and excluded triplets, SNPs for which
one nucleotide was unknown, and SNPs that had different nucle-
otides in different datasets. This was our QC procedure for all large
summary-statistics datasets that we analyzed. After QC, the ISC
A B
C D
Figure 2. Comparison of Four Prediction
Methods Applied to Simulated Traits
Prediction accuracy of the four different
methods listed in Table S1 when applied
to simulated traits with WTCCC geno-
types. The four subfigures correspond to
p ¼ 1 (A), p ¼ 0.1 (B), p ¼ 0.01 (C), and
p ¼ 0.001 (D) for the fraction of simulated
causal markers with (non-zero) effect sizes
sampled from a Gaussian distribution. To
aid interpretation of the results, we plot
the accuracy against the effective sample
size, defined as Neff ¼ ðN=MsimÞM, where
N ¼ 10,786 is the training sample size,
M ¼ 376,901 is the total number of SNPs,
and Msim is the actual number of SNPs
used in each simulation: 376,901 (all chro-
mosomes), 112,185 (chromosomes 1–4),
61,689 (chromosomes 1 and 2), and
30,004 (chromosome 1). The effective
sample size is the sample size that main-
tains the same N/M ratio if all SNPs are
used.
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cohort consisted of 1,562 affected and 1,994 control individuals
genotyped on ~518,000 SNPs that overlapped with the GWAS
summary statistics. The MGS dataset consisted of 2,681 affected
and 2,653 control individuals after QC and had ~549,000 SNPs
that overlapped with the GWAS summary statistics.
For multiple sclerosis (MS), we used the International Multiple
Sclerosis Genetics Consortium summary statistics.42 These were
calculated with 9,772 affected and 17,376 control individuals
(27,148 individuals in total) for ~465,000 SNPs. As an indepen-
dent validation dataset, we used the BWH/MIGEN chip genotypes
with 821 affected and 2,705 control individuals.43 All subjects pro-
vided informed consent for this research, and procedures followed
were in accordance with ethical standards. After QC, the overlap
between the validation genotypes and the summary statistics
only consisted of ~114,000 SNPs, which we used for our analysis.
For breast cancer (BC), we used the Genetic Associations and
Mechanisms in Oncology (GAME-ON) BC GWAS summary statis-
tics, consisting of 16,003 affected and 41,335 control individuals
(both estrogen-receptor-negative [ER] and -positive [ERþ] individ-
uals were included in this analysis).44–47 These summary statistics
were calculated for 2.6 million HapMap2 imputed SNPs. As valida-
tion genotypes, we combined genotypes from five different data-
sets: (1) ER and control individuals from the Breast and Prostate
Cancer Cohort Consortium (BPC3),44 (2) individuals from the
Nurses’ Health Study 2 (NHS2) breast cancer study (BrCa), (3)
affected and control individuals from the Nurses’ Health Study 1
(NHS1) mammographic density study, (4) NHS1 individuals
from the Cancer Genetic Markers of Susceptibility (CGEMS)
study,48 and (5) control individuals from the NHS2 kidney stone
study. All subjects in each cohort provided informed consent for
this research, and procedures followed were in accordance with
ethical standards. None of these 307 affected or 560 control indi-
viduals were included in the GWAS summary-statistics analysis,
and they thus represent an independent validation dataset. We
used the chip genotypes that overlapped the GWAS summary sta-
tistics, which resulted in ~444,000 genotypes after QC.
For CAD, we used the transatlantic Coronary Artery Disease
Genome-wide Replication and Meta-analysis (CARDIoGRAM)
consortium GWAS summary statistics. These were calculated
with 22,233 affected and 64,762 control individuals (86,995 indi-
viduals in total) for 2.4 million SNPs.10 For T2D, we used the
Diabetes Genetics Replication andMeta-analysis (DIAGRAM) con-
sortium GWAS summary statistics. These were calculated with
12,171 affected and 56,862 control individuals (69,033 individ-
uals in total) for 2.5 million SNPs.49 For both CAD and T2D, we
used the Women’s Genomes Health Study (WGHS) dataset as vali-
dation data,50 where we randomly down-sampled the control
individuals. For CAD, we validated the predictions in 923 individ-
uals with cardiovascular disease and 1,428 control individuals, and
for T2D we used 1,673 affected and 1,434 control individuals. We
used the genotyped SNPs that overlapped the GWAS summary sta-
tistics, which amounted to about ~290,000 SNPs for both CAD
and T2D after QC. All WGHS subjects provided informed consent
for this research, and procedures followed were in accordance with
ethical standards.
For height, we used the Genetic Investigation of Anthropo-
metric Traits (GIANT) GWAS summary statistics as published in
Lango Allen et al.6 These were calculated with 133,653 individ-
uals and imputed to 2.8 million HapMap2 SNPs. As a validation
cohort, we used the Mount Sinai Medical Center BioMe cohort,
which consists of 2,013 individuals and was genotyped at
~646,000 SNPs. All subjects provided informed consent for this
research, and procedures followed were in accordance with
ethical standards. After QC, the remaining ~539,000 SNPs that
overlapped the GWAS summary statistics were used for the
analysis.
For all six of these traits, we used the validation dataset as the LD
reference data when using LDpred and when performing LD prun-
ing. By using the validation dataset as LD reference data, we were
only required to coordinate two different datasets, i.e., the GWAS
summary statistics and the validation dataset. We calculated PþT
risk scores for different p value thresholds by using grid values
(1E8, 1E6, 1E5, 3E5, 1E4, 3E4, 1E3, 3E3, 0.01, 0.03,
0.1, 0.3, 1), and for LDpred we used the mixture probability (frac-
tion of causal markers) values (1E4, 3E4, 1E3, 3E3, 0.01,
0.03, 0.1, 0.3, 1). We then reported the optimal prediction value
from a validation dataset for LDpred and PþT.
SCZ Validation Datasets with Non-European Ancestry
For the non-European validation datasets, we used the MGS data-
set as an LD reference, given that the summary statistics were ob-
tained with individuals of European ancestry. This required us to
coordinate across three different datasets: the GWAS summary
statistics, the LD reference genotypes, and the validation geno-
types. To ensure sufficient overlap of genetic variants across all
three datasets, we used 1000 Genomes imputed MGS genotypes
and the 1000 Genomes imputed validation genotypes for the
three Asian validation datasets (JPN1, TCR1, and HOK2). To limit
the number of markers for these datasets, we only considered
markers that had a MAF > 0.1. After performing QC and
removing variants with a MAF < 0.1, we were left with 1.38
million SNPs and 492 affected and 427 control individuals in
the JPN1 dataset, 1.88 million SNPs and 898 affected and 973
control individuals in the TCR1 dataset, and 1.71 million SNPs
and 476 affected and 2,018 control individuals in the HOK2
dataset.
For the African-American (AFAM) validation dataset, we used
the reported GWAS summary-statistics dataset14 to train on. The
AFAM dataset consisted of 3,361 SCZ-affected and 5,076 control
individuals. Because the AFAM dataset was not included in that
analysis, this allowed us to leverage a larger sample size, but at
the cost of having fewer SNPs. The overlap among the 1000 Ge-
nomes imputedMGS genotypes, the HapMap 3 imputed AFAM ge-
notypes, and the PGC2 reported summary statistics included
~482,000 SNPs (with a MAF > 0.01) after QC. All subjects in the
JPN1, TCR1, HOK2, and AFAM datasets provided informed con-
sent for this research, and procedures followed were in accordance
with ethical standards.
Prediction-Accuracy Metrics
For quantitative traits, we used squared correlation (R2). For case-
control traits, which include all of the disease datasets analyzed,
we used four different metrics. We used Nagelkerke R2 as our pri-
mary figure of merit in order to be consistent with previous
work,1,9,12,14 but we also report three other commonly used met-
rics in Tables S2, S5, S7, and S10: observed-scale R2, liability-scale
R2, and the area under the curve (AUC). All of the reported predic-
tion R2 values were adjusted for the top five principal components
(PCs) in the validation sample (top three PCs for BC). The relation-
ship among the observed-scale R2, liability-scale R2, and AUC is
described in Lee et al.51 We note that Nagelkerke R2 is similar to
the observed-scale R2 (i.e., is also affected by case-control ascer-
tainment) but generally has slightly larger values.
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Results
Simulations
We first considered simulations with simulated genotypes
(see Material and Methods). We assessed accuracy by using
squared correlation (prediction R2) between observed and
predicted phenotypes. The Bayesian shrink imposed by
LDpred generally performed well in simulations without
LD (Figure S3); in this case, posterior mean effect sizes
can be obtained analytically (see Material and Methods).
However, LDpred performed particularly well in simula-
tions with LD (Figure S4); the larger improvement (e.g.,
versus PþT) in this case indicates that the main advantage
of LDpred is in its explicit modeling of LD. Simulations un-
der a Laplace mixture distribution prior gave similar results
(see Figure S5). We also evaluated the prediction accuracy
as a function of the sample size of the LD reference panel
(Figure S6). LDpred performs best with an LD reference
panel of at least 1,000 individuals. These results also high-
light the importance of using an LD reference population
with LD patterns similar to the training sample, given
that an inaccurate reference sample will have effects
similar to those of a small reference sample. Below, we
focus on simulations with real WTCCC genotypes, which
have more realistic LD properties.
Using real WTCCC genotypes41 (15,835 samples and
376,901 markers after QC), we simulated infinitesimal traits
with the heritability set to 0.5 (see Material and Methods).
We extrapolated results for larger sample sizes (Neff) by re-
stricting the simulations to a subset of the genome (smaller
M), leading to larger N/M. Results are displayed in
Figure 2A. LDpred-inf and LDpred (which are expected to
Figure 3. Comparison of Methods
Applied to SevenWTCCCDiseaseDatasets
The prediction accuracy of different
methodsas estimated from5-foldcross-vali-
dation in seven WTCCC disease datasets:
type 1 diabetes (T1D), rheumatoid arthritis
(RA), Crohn disease (CD), bipolar disease
(BD), type 2 diabetes (T2D), hypertension
(HT), and coronary artery disease (CAD).
The Nagelkerke prediction R2 is shown on
the y axis (see Table S2 for other metrics).
LDpred significantly improved the predic-
tion accuracy for the immune-related dis-
eases T1D, RA, and CD (see main text).
be equivalent in the infinitesimal
case) performed well in these simula-
tions—particularly at large values of
Neff, consistent with the intuition
from Equation 1 that the LD adjust-
ment arising from the reference-panel
LD matrix (D) is more important
when Nh2g=M is large. On the other
hand, PþT performed less well, consis-
tent with the intuition that pruning
markers loses information.
We next simulated non-infinitesimal traits by using real
WTCCC genotypes and varying the proportion p of causal
markers (see Material and Methods). Results are displayed
in Figures 2B–2D. LDpred outperformed all other ap-
proaches, including PþT, particularly at large values of
N/M. For p ¼ 0.01 and p ¼ 0.001, the methods that do
not account for non-infinitesimal architectures (unad-
justed PRSs and LDpred-inf) performed poorly, and PþT
was second best among these methods. Comparisons to
additional methods are provided in Figure S7; in particular,
LDpred outperformed other recently proposed approaches
that use LD from a reference panel13,52 (see Appendix B).
Besides accuracy (prediction R2), another measure of in-
terest is calibration. A predictor is correctly calibrated if a
regression of the true phenotype versus the predictor yields
a slope of 1 and is miscalibrated otherwise; calibration is
particularly important for risk prediction in clinical set-
tings. In general, unadjusted PRSs and PþT yield poorly
calibrated risk scores. On the other hand, the Bayesian
approach provides correctly calibrated predictions (if the
prior accurately models the true genetic architecture and
the LD is appropriately accounted for), avoiding the need
for re-calibration at the validation stage. The calibration
slopes for the simulations using WTCCC genotypes are
given in Figure S8. As expected, LDpred providesmuch bet-
ter calibration than other approaches.
Application to WTCCC Disease Datasets
We compared LDpred to other summary-statistics-based
methods across the seven WTCCC disease datasets41 by
using 5-fold cross-validation (see Material and Methods).
Results are displayed in Figure 3. (We used Nagelkerke R2
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as our primary figure of merit in order to be consistent with
previous work,1,9,12,14 but we also provide results for
observed-scale R2, liability-scale R2,51 and AUC53 in Table
S2; the relationship between these metrics is discussed in
the Material and Methods.)
LDpred attained significant improvement in prediction
accuracy over PþT for T1D (p value ¼ 4.4E15), RA
(p value ¼ 1.2E5), and CD (p value ¼ 2.7E8), similar
to previous results from BSLMM26, BayesR,28 and Multi-
BLUP27 on the same data. For these three immune-related
disorders, themajor histocompatibility complex (MHC) re-
gion explains a large amount of the overall variance, such
that it represents an extreme special case of a non-infinites-
imal genetic architecture. We note that LDpred, BSLMM,
and BayesR all explicitly model non-infinitesimal architec-
tures; however, unlike LDpred, BSLMM and BayesR require
full genotype data and cannot be applied to large sum-
mary-statistics datasets (see below). MultiBLUP, which
also requires full genotype data, assumes an infinitesimal
prior that varies across regions and thus benefits from a
different modeling extension; the possibility of extending
multiBLUP to work with summary statistics is a direction
for future research. For the other diseases with more-com-
plex genetic architectures, the prediction accuracy of
LDpred was similar to that of PþT, potentially because
the training sample size was not sufficiently large enough
for modeling LD to have a sizeable impact. The inferred
heritability parameters and optimal p parameters for
LDpred, as well as the optimal thresholding parameters
for PþT, are provided in Table S3. The calibration of the
predictions for the different approaches is shown in Table
S4. Consistent with our simulations, LDpred provides
much better calibration than other approaches.
Application to Six Large Summary-Statistics Datasets
We applied LDpred to five diseases—SCZ, MS, BC, T2D,
and CAD—for which we had GWAS summary statistics
for large sample sizes (ranging from ~27,000 to ~86,000
individuals) and raw genotypes for an independent valida-
tion dataset (see Material and Methods). Prediction accu-
racies for LDpred and other methods are reported in
Figure 4 (Nagelkerke R2) and Table S5 (other metrics). We
also applied LDpred to height (a quantitative trait), for
which we had GWAS summary statistics calculated with
~134,000 individuals6 and an independent validation da-
taset. The height-prediction accuracy for LDpred and other
methods is reported in Table S6.
For all six traits, LDpred provided significantly better
predictions than other approaches (for the improvement
over PþT, the p values were 6.3E47 for SCZ, 2.0E14
for MS, 0.020 for BC, 0.004 for T2D, 0.017 for CAD, and
1.5E10 for height). The relative increase in Nagelkerke
R2 over other approaches ranged from 11% for T2D to
25% for SCZ, and we observed a 30% increase in prediction
R2 for height. This is consistent with the fact that our sim-
ulations showed larger improvements for highly polygenic
traits, such as SCZ14 and height.54 We note that for both
CAD and T2D, the accuracy attained with >60,000
training samples from large meta-analyses (Figure 4) is
actually lower than the accuracy attained with <5,000
training samples from the WTCCC (Figure 3). This result
is independent of the predictionmethod applied and dem-
onstrates the challenges of potential heterogeneity in large
meta-analyses (although prediction results based on cross-
validation in a single cohort should be viewed with
caution19). To examine this further, we trained CAD and
T2D PRSs on the WTCCC data, validated them in the
WGHS data, and determined that the prediction accuracy
in external WGHS validation data is substantially smaller
than within the WTCCC dataset (Table S7). Possible expla-
nations for this discrepancy include differences in sample
ascertainment in theWGHS andWTCCC datasets or unad-
justed data artifacts in the WTCCC training and validation
data.
Parameters inferred by LDpred and other methods are
provided in Table S8, and calibration results are provided
Figure 4. Comparison of Methods
Training on Large GWAS Summary Statis-
tics for Five Different Diseases
The prediction accuracy is shown for five
different diseases: schizophrenia (SCZ),
multiple sclerosis (MS), breast cancer
(BC), type 2 diabetes (T2D), and coronary
artery disease (CAD). The risk scores were
trained with large GWAS summary-statis-
tics datasets and used for predicting disease
risk in independent validation datasets.
The Nagelkerke prediction R2 is shown on
the y axis (see Table S5 for other metrics).
Compared to LD pruning þ thresholding
(PþT), LDpred improved the prediction
R2 by 11%–25%. SCZ results are shown
for the SCZ-MGS validation cohort used
in recent studies,9,12,14 but LDpred also
produced a large improvement for the in-
dependent SCZ-ISC validation cohort
(Table S5).
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in Table S9; again, LDpred attained the best calibration.
Finally, we applied LDpred to predict SCZ risk in non-Euro-
pean validation samples of both African and Asian descent
(see Material and Methods). Although prediction accu-
racies were lower in absolute terms, we observed similar
relative improvements for LDpred over other methods
(Tables S10 and S11).
Discussion
PRSs are likely to become clinically useful as GWAS sam-
ple sizes continue to grow.15,18 However, unless LD is
appropriately modeled, their predictive accuracy will
fall short of their maximal potential. Our results show
that LDpred is able to address this problem—even
when only summary statistics are available—by esti-
mating posterior mean effect sizes by using a point-
normal prior and LD information from a reference panel.
Intuitively, there are two reasons for the relative gain in
prediction accuracy of LDpred PRSs over PþT. First, LD
pruning discards informative markers and thereby limits
the overall heritability explained by the markers. Second,
LDpred accounts for the effects of linked markers, which
can otherwise lead to biased estimates. These limitations
hinder PþT regardless of the LD pruning and p value
thresholds used.
Although we focus here on methods that only require
summary statistics, we note the parallel advances that
have been made in methods that require raw geno-
types22,24–29,55,56 as training data. Some of those methods
employ a variational Bayes (iterative conditional expecta-
tion) approach to reduce their running time24,25,29,55
(and report that results are similar to those of MCMC29),
but we found that MCMC generally obtains more robust
results than variational Bayes in the analysis of summary
statistics, perhaps because the LD information is only
approximate. Our use of a point-normal mixture prior is
consistent with some of those studies,25 although different
priors, e.g., a mixture of normal, were used by other
studies.23,26,28 One recent study proposed an elegant
approach for handling case-control ascertainment while
including genome-wide-significant associations as fixed ef-
fects;56 however, the correlations between distal causal
SNPs induced by case-control ascertainment do not affect
summary statistics from marginal analyses, and explicit
modeling of non-infinitesimal effect-size distributions
will appropriately avoid shrinking genome-wide-signifi-
cant associations (Figure S2).
Although LDpred is a substantial improvement over ex-
isting methods for using summary statistics to conduct
polygenic prediction, it still has limitations. First, the
method’s reliance on LD information from a reference
panel requires that the reference panel be a good match
for the population from which summary statistics were ob-
tained; in the case of a mismatch, prediction accuracy
might be compromised. One potential solution is the
broad sharing of summary LD statistics, which has previ-
ously been advocated in other settings.57 If LDpred uses
the true LD pattern from the training sample, and there
is no unaccounted long-range LD, then we expect little
or no gain in prediction accuracy with individual-level ge-
notype information. Second, the point-normal mixture
prior distribution used by LDpred might not accurately
model the true genetic architecture, and it is possible
that other prior distributions might perform better in
some settings. Third, in those instances where raw geno-
types are available, fitting all markers simultaneously (if
computationally tractable) might achieve higher accuracy
than methods based on marginal summary statistics.
Fourth, as with other prediction methods, heterogeneity
across cohorts might hinder prediction accuracy; our re-
sults suggest that this could be amajor concern in some da-
tasets. Fifth, we assume that summary statistics have been
appropriately corrected for genetic ancestry, but if this is
not the case, then the prediction accuracy might be misin-
terpreted19 or might even decrease.58 Sixth, our analyses
have focused on common variants; LD reference panels
are likely to be inadequate for rare variants, motivating
future work on how to treat rare variants in PRSs. Despite
these limitations, LDpred is likely to be broadly useful in
leveraging summary-statistics datasets for polygenic pre-
diction of both quantitative and case-control traits.
As sample sizes increase and polygenic predictions
become more accurate, their value increases, both in clin-
ical settings and for understanding genetics. LDpred repre-
sents substantial progress, but more work remains to be
done. One future direction would be to develop methods
that combine different sources of information. For
example, as demonstrated by Maier et al.,59 joint analysis
of multiple traits can increase prediction accuracy. In addi-
tion, using different prior distributions across genomic re-
gions27 or functional annotation classes60 could further
improve the prediction. Finally, although LDpred attains
a similar relative improvement when using non-European
samples as validation samples, the lower absolute accuracy
than in European samples motivates further efforts to
improve prediction in diverse populations.
Appendix A: Estimating the Posterior Mean
Phenotype
Under the assumption that the phenotype has an additive
genetic architecture and is linear, then estimating the pos-
terior mean phenotype boils down to estimating the poste-
rior mean effects of each SNP and then summing their
contribution in a risk score.
Posterior Mean Effects Assuming Unlinked Markers
and an Infinitesimal Model
Wewill first consider the infinitesimal model, which repre-
sents a genetic architecture where all genetic variants
are causal. The classic example is Fisher’s infinitesimal
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model,37 which assumes that genotypes are unlinked and
that effect sizes have a Gaussian distribution (after normal-
izing by allele frequency).
Assume that bi are independently drawn from a
Gaussian distribution bi  Nð0; ðh2=MÞÞ, where M denotes
the total number of causal effects ðbiÞ. Then, we can derive
a posterior mean given the marginal ordinary least-squares
estimate ~bi ¼ ðXiYÞ=N. The least-squares estimate is
approximately distributed as
~bi  N
 
bi;
1 h
2
M
N
!
;
where N is the number of individuals. The variance can be
approximated further, VarðbiÞz1, when M is large. With
this variance, the posterior distribution for bi is
bi j ~bi  N
  
1
1þ M
h2N
!
~bi;
1
N
 
1
1þ M
h2N
!!
:
This suggests that a uniform Bayesian shrink by a factor of
1
1þ M
h2N
is appropriate under Fisher’s infinitesimal model.
Other possible choices of prior distributions for the ef-
fects include Laplace distributions. However, calculating
the posterior mean under this model is non-trivial but
can be solved numerically.61 Alternatively, the posterior
mode has a simple analytical form.62 The posterior mode
under a Laplace prior is in fact the LASSO estimate.63 If
we assume that the sum of the effects has variance h2
and that the genetic markers are uncorrelated, then the
posterior mode estimate is
_bi ¼ signðbiÞmax
 
0; j bi j 
ﬃﬃﬃﬃﬃﬃﬃﬃ
h2
2M
r !
:
Interestingly, the posterior mode effects for estimated
effects below a given threshold are set to 0, even though
all betas are causal in the model.
Posterior Mean Effects Assuming Unlinked Markers
and a Non-infinitesimal Model
Most diseases and traits are not likely to be strictly infini-
tesimal, i.e., follow Fisher’s infinitesimal model.37 Instead,
a non-infinitesimal model, where only a fraction of the ge-
netic variants are truly causal and affect the trait, is more
likely to describe the underlying genetic architecture. We
canmodel non-infinitesimal genetic architectures by using
mixture distributions with a mixture parameter p, which
denotes the fraction of causal markers. More specifically,
we will consider a spike-and-slab prior with a 0 spike and
a Gaussian slab (see Figure S9).
Assume that the effects are drawn from a mixture distri-
bution as follows:
bi 
8><>:N

0;
h2
Mp
	
with probability p
0 with probability ð1 pÞ
:
Another way of writing this is to use Dirac’s delta func-
tion, i.e., write bi ¼ puþ ð1 pÞv, where u  ð0; ðh2=MpÞÞ
and v  dbi . Here, dbi denotes the point density at bi ¼ 0,
which integrates to 1. We can then write out the density
for ~bi as follows:
f

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We are interested in the posterior mean, which can be ex-
pressed as
E

bi j ~bi
 ¼ ZN
N
bif

~bi j bi

f ðbiÞRN
N f

~bi j bi

f ðbiÞdbi
dbi :
Hence, we only need to calculate the following definite
integral:ZN
N
bif

~bi j bi

f ðbiÞdbi ¼
p
2p
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Thus, the posterior mean is
E
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where
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Alternatively, by realizing that the posterior probability
that bi is sampled from the Gaussian distribution given ~bi
is exactly
we can rewrite the posterior mean in a simpler fashion. If
we let pi ¼ Pðbi  Nð,; ,Þ
~biÞ denote the posterior probabil-
ity that bi is non-zero or Gaussian distributed (Equation
A1), then it becomes
E

bi j ~bi
 ¼
 
1
1þ Mp
h2N
!
pi
~bi :
Posterior Mean Effects Assuming Linked Markers and
an Infinitesimal Model
Following Yang et al.,52 we can obtain the joint least-
squares effect estimates as
bbjoint ¼ D1~bmarg;
where D ¼ XX0=N is the LD correlation matrix, and ~b de-
notes the vector of marginal least-squares effects (which
is approximately equal to the joint least-squares estimate
if SNPs are unlinked). In practice, the LD matrix is M3M
and possibly singular, e.g., if two (or more) markers are in
perfect linkage. If the LD matrix D is singular, the joint
least-squares estimate does not have a unique solution.
However, if the individuals in the training data do not
display family or population structure, the genome-wide
LDmatrix is approximately a banded matrix, which allows
local adjustment for LD instead. To formalize these ideas,
we introduce some notation. Let li denote the i
th locus or
region withMli markers. In addition, let b
ðiÞ denote the vec-
tor of true effects that are in the ith region, and similarly let
~b
ðiÞ
denote the corresponding marginal least-squares esti-
mates in the region. Under this model, we can derive the
sampling distribution for effect estimates at the ith region,
i.e., ~b
ðiÞ bðiÞ. The mean is Eð~bðiÞ bðiÞÞ ¼ DðiÞbðiÞ, where
DðiÞ ¼ XðiÞXðiÞ0=N is the LD matrix obtained from the
markers in the ith region, i.e., XðiÞ. Furthermore, the condi-
tional covariance matrix is
Var

~b
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E
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where h2li denotes the heritability explained by the
markers in the region, i.e., XðiÞ. If we assume that the heri-
tability explained by an individual region is small, then
this simplifies to Varð~bðiÞ  bðiÞÞ ¼ DðiÞ=N. This equation is
C ¼
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ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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(Equation A1)
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particularly useful for performing efficient simulations of
effect sizes without simulating the genotypes. Given an
LD matrix, D, we can simulate effect sizes and correspond-
ing least-squares estimates. Similarly, for the joint estimate,
we have
E
bbðiÞjoint j bðiÞ ¼ bðiÞ
and
Var
bbðiÞjoint j bðiÞ ¼ 1 h2liN DðiÞ1:
In the following, we let b (and ~b) denote the effects
within a region of LD. We furthermore assume that these
markers only explain a fraction, h2l , of the total phenotypic
variance, and h2l%h
2. Given a Gaussian prior distribution
b  Nð0; ðh2=MÞÞ for the effects and the conditional distri-
bution ~b
b, we can derive the posterior mean by consid-
ering the joint density:
f

~b; b
 ¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃjD jp
0@ N
2p

1 h2l

1AM2
3 exp
8<:N

~bDb0D1~bDb
2

1 h2l

9=;

Mp
2ph2
	M
2
3 exp


M
2h2
b0b

:
We can now obtain the posterior density for ~b
 b by
completing the square in the exponential. This yields a
multivariate Gaussian with mean and variance as follows:
E

b j ~b ¼  1
1 h2l
Dþ M
Nh2
I
!1
~b ;
Var

b j ~b ¼ 1
N
 
1
1 h2l
Dþ M
Nh2
I
!1
;
where h2 denotes the heritability explained by theM causal
variants, and h2lzkh
2=M is the heritability of the k effects
or variants in the region of LD. If M[ k, then 1 h2l be-
comes approximately 1, and the equations above can be
simplified accordingly. As expected, the posterior mean
approaches the maximum-likelihood estimator as the
training sample size grows.
Posterior Mean Effects Assuming Linked Markers and
a Non-infinitesimal Model
The Bayesian shrink under the infinitesimal model implies
that we can solve it either by using a Gauss-Seidel
method64,65 or via MCMC Gibbs sampling. The Gauss-
Seidel method iterates over the markers and obtains a
residual effect estimate after subtracting the effect of
neighboring markers in LD. It then applies a univariate
Bayesian shrink, i.e., the Bayesian shrink for unlinked
markers (described above). It then iterates over the genome
multiple times until convergence is achieved. However, we
found the Gauss-Seidel approach to be sensitive to model
assumptions, i.e., if the LD matrix used differed from the
true LD matrix in the training data, we observed conver-
gence issues. We therefore decided to use an approximate
MCMC Gibbs sampler instead to infer the posterior
mean. The approximate Gibbs sampler used by LDpred is
similar to the Gauss-Seidel approach, except that instead
of using the posterior mean to update the effect size, we
sample the update from the posterior distribution.
Compared to the Gauss-Seidel method, this seems to lead
to less serious convergence issues. Below, we describe the
Gibbs sampler used by LDpred.
Define q as follows:
q 


1 with probability p
0 with probability ð1 pÞ :
Then, we can write b ¼ qu, where u  Nð0; ðh2=MpÞIÞ.
Hence, we can write the multivariate density for b as
f ðbÞ ¼
YM
i¼1
 
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Mp
2ph2
r
exp


 Mp
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b2i

þ ð1 pÞdbi
!
:
The sampling distribution for ~b given b is
f

~b j b ¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃjD jp
0@ N
2p

1 h2l

1AM2
3 exp
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2
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(Equation A2)
As usual, we want to calculate the posterior mean, i.e.,
E

b j ~b ¼ Z bif ~b j bf ðbÞR
f

~b j bf ðbÞdb db;
which now consists of twoM-dimensional integrands. Any
multiplicative term that does not involve b in the two
integrands factors out. Because the integrand consists of
2M nontrivial additive terms, we result to numerical ap-
proximations to sample from the posterior and estimate
the posterior mean effects.
An alternative approach to obtaining the posterior
mean is to sample from the posterior distribution and
then average over the samples to obtain the posterior
mean. In our case, we know the posterior up to a
constant, i.e.,
f

b j ~bff b; ~b ¼ f ~b j bf ðbi j biÞf ðbiÞ;
where bi denotes all the other effects except for the effect
of the ith marker. Note that ðbi j biÞf ðbiÞ ¼ f ðbÞ. We can
use this fact to sample efficiently in a MCMC setting,
where we sample one marker effect at a time in an iterative
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fashion (the conditional proposal distribution is therefore
univariate).
A Gibbs sampler is an efficient MCMC that can be
used whenever the marginal conditional posterior distri-
butions can be derived. For our purposes, these are the
conditional posterior distributions of the effects, i.e.,
f ðb j ~b; biÞ, where bi refers to the vector of betas
excluding the ith beta. We can write the posterior distribu-
tion as follows:
f

b j ~b; bi
 ¼ f ~b; b
f

~b; bi
 ¼ f ~b j bf ðbÞ
f

~b j bi

f ðbiÞ
¼ f

~b j bf ðbiÞ
f

~b j bi

¼ f

~b j bf ðbiÞR
f

~b j bf ðbiÞdbi :
Sampling from this distribution is not trivial. However,
we can partition the sampling procedure into two
parts, such that we first sample whether the effect is
different from 0 and then if it is different from 0, we can
assume it has a Gaussian prior. To achieve this, we first
need to calculate the posterior probability that a marker
is causal, i.e.,
P

bi ¼ 0 j ~b; bi
 ¼ Pbi ¼ 0; ~b; bi
P

~b; bi

¼ P

bi ¼ 0; ~b j bi

P

bi ¼ 0; ~b j bi
þ Z
bis0
f

~b j bf ðbiÞdbi:
Obtaining an analytical solution to this is non-trivial;
however, if we assume that Pðbi ¼ 0 j ~b; biÞz
Pðbi ¼ 0 j ~bi; biÞ, then we can simply extract the effects of
LD from other effects on the effect estimate ~bi and then
use the marginal posterior probability that the marker is
causal from Equation A1 instead, i.e., Pðbi ¼ 0 j ~bi; biÞz
pi. If we sample the effect to be non-zero and again
make the simplifying assumption that f ðbi j ~b; biÞz
f ðbi j ~bi; biÞ, then we can write out its posterior distribu-
tion, extract the effects of LD on the effect estimate, and
sample from the marginal (without LD) posterior distribu-
tion derived above. More specifically, the marginal poste-
rior distribution for bi becomes
f

bi j ~b; bi

zf

bi j ~bi; bi
 ¼ 1 pidbi þ pihðbiÞ;
where hðbiÞ is the Gaussian density for the posterior distri-
bution conditional on bis0, i.e.,
bi j ~bi; bi; bis0  N
  
1
1þ M
h2N
!
~bi;
1
N
 
1
1þ M
h2N
!!
:
Other Considerations for LDpred
Although LDpred aims to estimate the posterior mean
phenotype (the best unbiased prediction), it is only guar-
anteed to do so if all the assumptions hold. Because LDpred
relies on a few assumptions (both regarding LD and math-
ematical approximations), it is an approximate Gibbs
sampler, which can lead to robustness issues. Indeed, we
found LDpred to be sensitive to inaccurate LD estimates,
especially for very large sample sizes. To address this, we
set the probability of setting the effect size to 0 in the
Markov chain to be at least 5%. This improved the robust-
ness of LDpred as observed in both simulated and real data.
If convergence issues arise when LDpred is applied to data,
then it might be worthwhile to explore higher values for
the 0-jump probability.
Finally, throughout the above derivation of LDpred, we
assumed that the LD information in the training data
was known. However, in practice that information might
not be available, and instead we need to estimate the LD
pattern from a reference panel. As long as the LD reference
panel is representative and contains at least 1,000 individ-
uals, this assumption does not seem to affect performance
in simulations.
Appendix B: Conditional Joint Analysis
To understand the conditional joint (COJO) analysis as
proposed by Yang et al.,52 we implemented a stepwise
COJO analysis in LDpred. The COJO analysis estimates
the joint least-squares estimate from the marginal least-
squares estimate (obtained from GWAS summary statis-
tics). If we define D ¼ XX0=N, then we have the following
relationship:
bbjoint ¼ ðDÞ1~b :
This matrix D has dimensions M3M and might be
singular. However, as for LDpred, we can adjust for LD
locally if the individuals in the training data do not
display family or population structure, in which case the
genome-wide LD matrix is approximately a banded
matrix. In practice, COJO analysis with all SNPs suffers
a fundamental problem of statistical inference, i.e., it
infers a large number of parameters (M) by using N
samples. Hence, if N < M, we do not expect the method
to perform particularly well. We verified this in simula-
tions (see Figure S7A). By restricting to ‘‘top’’ SNPs and
accounting for LD by using a stepwise approach (as
proposed by Yang et al.52) we alleviate this concern. How-
ever, although this reduces overfitting when N < M, this
approach also risks discarding potentially informative
markers from the analysis. Nevertheless, by optimizing
the stopping threshold via cross-validation in an in-
dependent dataset, the method performs reasonably well
in practice, especially when the number of causal
markers in the genome is small. In contrast, LDpred
conditions on the sample size and accounts for the
noise term appropriately (under the model), leading to
improved prediction accuracies regardless of training
sample size.
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Supplemental Data include 9 figures and 11 tables and can be
found with this article online at http://dx.doi.org/10.1016/j.
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